Accessibility Statement Skip Navigation
  • Why PRWeb
  • How It Works
  • Who Uses It
  • Pricing
  • Login
  • GDPR
  • Create a Free Account
Return to PRWeb homepage
  • News
  • Resources
  • Contact
When typing in this field, a list of search results will appear and be automatically updated as you type.

Searching for your content...

No results found. Please change your search terms and try again.
  • News in Focus
      • Browse News Releases

      • All News Releases
      • Multimedia Gallery

      • All Multimedia
      • All Photos
      • All Videos
  • Business & Money
      • Auto & Transportation

      • Aerospace, Defense
      • Air Freight
      • Airlines & Aviation
      • Automotive
      • Maritime & Shipbuilding
      • Railroads and Intermodal Transportation
      • Supply Chain/Logistics
      • Transportation, Trucking & Railroad
      • Travel
      • Trucking and Road Transportation
      • View All Auto & Transportation

      • Business Technology

      • Blockchain
      • Broadcast Tech
      • Computer & Electronics
      • Computer Hardware
      • Computer Software
      • Data Analytics
      • Electronic Commerce
      • Electronic Components
      • Electronic Design Automation
      • Financial Technology
      • High Tech Security
      • Internet Technology
      • Nanotechnology
      • Networks
      • Peripherals
      • Semiconductors
      • View All Business Technology

      • Entertain­ment & Media

      • Advertising
      • Art
      • Books
      • Entertainment
      • Film and Motion Picture
      • Magazines
      • Music
      • Publishing & Information Services
      • Radio & Podcast
      • Television
      • View All Entertain­ment & Media

      • Financial Services & Investing

      • Accounting News & Issues
      • Acquisitions, Mergers and Takeovers
      • Banking & Financial Services
      • Bankruptcy
      • Bond & Stock Ratings
      • Conference Call Announcements
      • Contracts
      • Cryptocurrency
      • Dividends
      • Earnings
      • Earnings Forecasts & Projections
      • Financing Agreements
      • Insurance
      • Investments Opinions
      • Joint Ventures
      • Mutual Funds
      • Private Placement
      • Real Estate
      • Restructuring & Recapitalization
      • Sales Reports
      • Shareholder Activism
      • Shareholder Meetings
      • Stock Offering
      • Stock Split
      • Venture Capital
      • View All Financial Services & Investing

      • General Business

      • Awards
      • Commercial Real Estate
      • Corporate Expansion
      • Earnings
      • Environmental, Social and Governance (ESG)
      • Human Resource & Workforce Management
      • Licensing
      • New Products & Services
      • Obituaries
      • Outsourcing Businesses
      • Overseas Real Estate (non-US)
      • Personnel Announcements
      • Real Estate Transactions
      • Residential Real Estate
      • Small Business Services
      • Socially Responsible Investing
      • Surveys, Polls and Research
      • Trade Show News
      • View All General Business

  • Science & Tech
      • Consumer Technology

      • Artificial Intelligence
      • Blockchain
      • Cloud Computing/Internet of Things
      • Computer Electronics
      • Computer Hardware
      • Computer Software
      • Consumer Electronics
      • Cryptocurrency
      • Data Analytics
      • Electronic Commerce
      • Electronic Gaming
      • Financial Technology
      • Mobile Entertainment
      • Multimedia & Internet
      • Peripherals
      • Social Media
      • STEM (Science, Tech, Engineering, Math)
      • Supply Chain/Logistics
      • Wireless Communications
      • View All Consumer Technology

      • Energy & Natural Resources

      • Alternative Energies
      • Chemical
      • Electrical Utilities
      • Gas
      • General Manufacturing
      • Mining
      • Mining & Metals
      • Oil & Energy
      • Oil and Gas Discoveries
      • Utilities
      • Water Utilities
      • View All Energy & Natural Resources

      • Environ­ment

      • Conservation & Recycling
      • Environmental Issues
      • Environmental Policy
      • Environmental Products & Services
      • Green Technology
      • Natural Disasters
      • View All Environ­ment

      • Heavy Industry & Manufacturing

      • Aerospace & Defense
      • Agriculture
      • Chemical
      • Construction & Building
      • General Manufacturing
      • HVAC (Heating, Ventilation and Air-Conditioning)
      • Machinery
      • Machine Tools, Metalworking and Metallurgy
      • Mining
      • Mining & Metals
      • Paper, Forest Products & Containers
      • Precious Metals
      • Textiles
      • Tobacco
      • View All Heavy Industry & Manufacturing

      • Telecomm­unications

      • Carriers and Services
      • Mobile Entertainment
      • Networks
      • Peripherals
      • Telecommunications Equipment
      • Telecommunications Industry
      • VoIP (Voice over Internet Protocol)
      • Wireless Communications
      • View All Telecomm­unications

  • Lifestyle & Health
      • Consumer Products & Retail

      • Animals & Pets
      • Beers, Wines and Spirits
      • Beverages
      • Bridal Services
      • Cannabis
      • Cosmetics and Personal Care
      • Fashion
      • Food & Beverages
      • Furniture and Furnishings
      • Home Improvement
      • Household, Consumer & Cosmetics
      • Household Products
      • Jewelry
      • Non-Alcoholic Beverages
      • Office Products
      • Organic Food
      • Product Recalls
      • Restaurants
      • Retail
      • Supermarkets
      • Toys
      • View All Consumer Products & Retail

      • Entertain­ment & Media

      • Advertising
      • Art
      • Books
      • Entertainment
      • Film and Motion Picture
      • Magazines
      • Music
      • Publishing & Information Services
      • Radio & Podcast
      • Television
      • View All Entertain­ment & Media

      • Health

      • Biometrics
      • Biotechnology
      • Clinical Trials & Medical Discoveries
      • Dentistry
      • FDA Approval
      • Fitness/Wellness
      • Health Care & Hospitals
      • Health Insurance
      • Infection Control
      • International Medical Approval
      • Medical Equipment
      • Medical Pharmaceuticals
      • Mental Health
      • Pharmaceuticals
      • Supplementary Medicine
      • View All Health

      • Sports

      • General Sports
      • Outdoors, Camping & Hiking
      • Sporting Events
      • Sports Equipment & Accessories
      • View All Sports

      • Travel

      • Amusement Parks and Tourist Attractions
      • Gambling & Casinos
      • Hotels and Resorts
      • Leisure & Tourism
      • Outdoors, Camping & Hiking
      • Passenger Aviation
      • Travel Industry
      • View All Travel

  • Policy & Public Interest
      • Policy & Public Interest

      • Advocacy Group Opinion
      • Animal Welfare
      • Congressional & Presidential Campaigns
      • Corporate Social Responsibility
      • Domestic Policy
      • Economic News, Trends, Analysis
      • Education
      • Environmental
      • European Government
      • FDA Approval
      • Federal and State Legislation
      • Federal Executive Branch & Agency
      • Foreign Policy & International Affairs
      • Homeland Security
      • Labor & Union
      • Legal Issues
      • Natural Disasters
      • Not For Profit
      • Patent Law
      • Public Safety
      • Trade Policy
      • U.S. State Policy
      • View All Policy & Public Interest

  • People & Culture
      • People & Culture

      • Aboriginal, First Nations & Native American
      • African American
      • Asian American
      • Children
      • Diversity, Equity & Inclusion
      • Hispanic
      • Lesbian, Gay & Bisexual
      • Men's Interest
      • People with Disabilities
      • Religion
      • Senior Citizens
      • Veterans
      • Women
      • View All People & Culture

  • Hamburger menu
  • Cision PRWeb provides efficient communication tools to continuously engage with target audiences across multiple online channels
  • Create a Free Account
    • ALL CONTACT INFO
    • Contact Us


      11AM ET Sunday – 8PM ET Friday

  • Send a Release
  • Sign up
  • Log in
  • Resources
  • RSS
  • GDPR
  • News in Focus
    • Browse All News
    • Multimedia Gallery
  • Business & Money
    • Auto & Transportation
    • Business Technology
    • Entertain­ment & Media
    • Financial Services & Investing
    • General Business
  • Science & Tech
    • Consumer Technology
    • Energy & Natural Resources
    • Environ­ment
    • Heavy Industry & Manufacturing
    • Telecomm­unications
  • Lifestyle & Health
    • Consumer Products & Retail
    • Entertain­ment & Media
    • Health
    • Sports
    • Travel
  • Policy & Public Interest
  • People & Culture
    • People & Culture
  • Send a Release
  • Sign up
  • Log in
  • Resources
  • RSS
  • GDPR
  • Send a Release
  • Sign up
  • Log in
  • Resources
  • RSS
  • GDPR
  • Send a Release
  • Sign up
  • Log in
  • Resources
  • RSS
  • GDPR

AkesoGenX Corp. Assumes Control of Kanzius Cancer Treatment Technology
  • USA - English


News provided by

[email protected]

Jan 15, 2014, 17:50 ET

Share this article

Share toX

Share this article

Share toX

Houston, TX (PRWEB) January 15, 2014 -- Located in Houston, Texas, AkesoGenX Corp. has acquired and assumed control of the intellectual property and equipment related to the Kanzius Cancer Treatment technology from Therm Med LLC. The AkesoGenX management team envisions taking John Kanzius’s patented Noninvasive Radio Wave Cancer Treatment from pre-FDA research through to human clinical trials, and if results are positive, to commercialization in concert with their strategic partners. The true goal is making this state-of-the-art technology available to treat those afflicted with cancer.

Origins
The reality of current cancer treatment is nothing short of life changing for thousands of patients and their families annually…no one understood this better than the late John Kanzius. The mission of AkesoGenX Corp. is to provide an alternative noninvasive cancer therapy, which will allow for an effective treatment for cancer patients while reducing side effects associated with traditional chemotherapies and radiation therapies.

The Team
The founding members of AkesoGenX Corp. originate from diverse yet complementary sectors within the medical, science and technology industries and bring years of experience and management expertise. The AkesoGenX management team will provide a solid foundation for the human clinical trials needed for commercialization of this innovative cancer treatment technology.

Dr Steven Curley
Renowned cancer specialist Dr. Curley will continue his role as lead researcher, now at Baylor College of Medicine in the Texas Medical Center. As a co-founder of AkesoGenX Corp., Dr. Curley will be focused on the direction and timing of FDA submission.

"I made a promise to my friend John Kanzius in 2008 that I would get his treatment into clinical trials in cancer patients.” said Dr. Curley “I told Nobel Laureate Professor Richard Smalley in 2005 that I would continue to work combining nano particles with the Kanzius RF field to find an effective, less toxic cancer treatment. I owe an eternal debt of gratitude to the Kanzius Cancer Research Foundation and to people everywhere who have supported the Foundation because this work would not have been possible without your optimism and unflagging support. To the people of Erie, Pennsylvania, Fort Myers, Florida and Sanibel Island, THANK YOU! I am confident this new venture will allow us to move this treatment forward in patients fighting against cancer, and I am excited about the future."

Robert Zavala, CEO
Co-founder and CEO of AkesoGenX Corp. Robert will be responsible for developing the strategic direction, mission critical partnerships and overall business operations required to move this innovative-patented technology into human clinical trials. Dr. Curley and Mr. Zavala are honored to lead the efforts toward making this treatment available to those afflicted with cancer. Robert’s expertise is within the nano-materials industry and because this cancer treatment is based in part on nano-technology, Robert’s experience in that industry will benefit AkesoGenX commercialization efforts.

“I’m honored to be a part of the team which has been led by Dr. Curley.” Said Robert, “AkesoGenX is looking forward to fulfilling the dream of the inventor of the technology, the late John Kanzius. Both Dr. Curley and I are grateful for all of the continued support we have received from the Kanzius Family, the Erie, Pennsylvania and Sanibel Island, Florida communities and the Kanzius Cancer Research Foundation.”

In a statement released today, Maryann, the widow of John Kanzius said, “We at Therm Med are very pleased that the technology invented by my late husband, John Kanzius, is in very capable hands with the scientific and business expertise necessary to take this very worthy project to the next level. We wish AkesoGenX the very best.”

AkesoGenX Vision
AkesoGenX Corp.’s strategic vision is to bring to market significant new nano-diagnostic and nano-therapeutic medical products. The primary goal is to move the Kanzius RF field treatment forward to treat patients with highly lethal and resistant forms of cancer.

More About AkesoGenX
AkesoGenX Corp. has offices in Colorado and is headquartered in Houston, Texas, in order to leverage deep and long-term relationships with the Baylor College of Medicine, the University of Texas MD Anderson Cancer Center, Rice University and Texas A&M University. In addition, the many medical institutions in the Texas Medical Center where the science of nanotechnology and of medical nano-therapeutics is underway in significant scale will be of great benefit to future development.

AkesoGenX Corp. formed around the novel ideas and inventions of John Kanzius, the brilliant research of Dr. Steven Curley and the advanced nanomaterial’s industry expertise of Robert Zavala.

More information:
http://www.AkesoGenx.com
Video:
http://www.youtube.com/watch?v=SFa75qJrjzE

Contact and Interview Requests:
Lucy Conlon
McCartney PR
Los Angeles
310-301-8166 xtn 221
310 901 8166
lucy(at)mccartney(dot)com

Keywords:
#cancer #nanotechnology #medicine #Kanzius #RF Radio Frequency

Lucy Conlon, [email protected], +1 (310) 301-8166 Ext: 221, [email protected]

Modal title

Contact PRWeb

  • 11AM ET Sunday – 8PM ET Friday
  • Contact Us

About PRWeb

  • About PRWeb
  • Partners
  • Partnership Programs
  • Editorial Guidelines
  • Resources

Why PRWeb

  • Why PRWeb
  • How It Works
  • Who Uses It
  • Pricing

Accounts

  • Create a Free Account
  • Log in
  • Contact Us

Do not sell or share my personal information:

  • Submit via [email protected] 
  • Call Privacy toll-free: 877-297-8921

Contact Cision

Products

About

My Services
  • All News Releases
  • Online Member Center
  • ProfNet
Cision Distribution Helpline
888-776-0942
  • Legal
  • Site Map
  • RSS
  • Cookie Settings
Copyright © 2025 Cision US Inc.